What is Guardant Health Operating Cash Flow per Share?
Guardant Health's operating cash flow per share for the
three
months ended in Dec. 2023 was $-0.66.
Guardant Health's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.91.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -39.60% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -22.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Guardant Health's Operating Cash Flow per Share or its related term are showing as below:
GH'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -79.9 Med: -1.4 Max: 4.6
Current: -39.6
During the past 8 years, Guardant Health's highest 3-Year average Operating Cash Flow per Share Growth Rate was 4.60% per year. The lowest was -79.90% per year. And the median was -1.40% per year.
GH's 3-Year OCF Growth Rate is ranked worse than 90.8% of 174
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.15
vs GH: -39.60
Guardant Health Operating Cash Flow per Share Historical Data
The historical data trend for Guardant Health's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Operating Cash Flow per Share Chart
Competitive Comparison of Guardant Health's Operating Cash Flow per Share
For the Diagnostics & Research subindustry, Guardant Health's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Guardant Health's Price-to-Operating-Cash-Flow falls into.
Guardant Health Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Guardant Health's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.91
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Guardant Health's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health (Guardant Health) Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 